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Abstract: Small interfering RNA (siRNA) molecules have significant therapeutic promise 
for the genetic treatment of cancer. To overcome instability and low transfection efficiency, 
polyethylene glycol-polyethyleneimine (PEG-PEI) was synthesized and investigated as a 
non-viral carrier of siRNA targeting CD44v6 in gastric carcinoma cells. The size, surface 
charge using zeta potential, and morphology via scanning electron microscopy (SEM) of 
PEG-PEI/siRNA nanoparticles was characterized, and their cytotoxicity, transfection efficiency, 
and interaction with SGC7901 human gastric carcinoma cells was evaluated. The transfection 
efficiency of PEG-PEI/siRNA nanocomplexes was dependant on the charge ratio between 
amino groups of PEG-PEI and phosphate groups of siRNA (N/P) values, which reflected the 
molar ratio of PEG-PEI to siRNA during complex formation. The transfection efficiency of 
PEG-PEI/siRNA at N/P 15 was 72.53% ± 2.38%, which was higher than that observed using 
Lipofectamine 2000 and PEI as delivery carriers. Cytotoxicity of PEG-PEI was determined by 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay and was obviously 
lower than that of PEI. Moreover, when N/P was below 15, PEG-PEI/siRNA was less toxic 
than Lipofectamine 2000/siRNA. RT-PCR (real time polymerase chain reaction) and Western 
blot analyses of CD44v6 expression demonstrated the gene silencing effect of PEG-PEI/siRNA 
at N/P 15. These data indicate that PEG-PEI may be a promising non-viral carrier for altering 
gene expression in the treatment of gastric cancer with many advantages, such as relatively 
high gene transfection efficiency and low cytotoxicity.
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Introduction
CD44 is a multifunctional cell adhesion molecule and a cell surface receptor of 
hyaluronan. In addition, it is involved in extracellular matrix binding, cell migration, 
and lymphocyte homing.1 There are a number of isoforms of CD44 resulting from 
alternative splicing, which includes the following: CD44s (the standard form), CD44E 
(the epithelial form), and CD44v (the variant isoform).2 CD44v isoforms, especially 
CD44v6, play an important role in tumor progression and metastasis of gastric 
cancer. CD44v6 expression is significantly higher in gastric cancer patients with liver 
metastasis.3 Moreover, the expression of CD44v6 is an independent risk factor for 
lymph node metastasis.4 Therefore, suppressing CD44v6 expression might postpone 
or inhibit the invasion and metastasis of gastric cancer.
RNA interference (RNAi) is an effective technology for gene silencing in gene 
therapy. Since the discovery of its mechanism, small interference RNA (siRNA) has 
been used for assaying gene function5,6 and potential therapeutics.7,8 A growing number 
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of studies have shown its therapeutic promise in treating 
various diseases, including cancer.9 However, siRNA is 
rapidly degraded and the uptake by target cells and tissues 
is often low.10 Therefore, development of an efficient siRNA 
delivery system is desperately demanded.
Carrier systems are essential to deliver siRNA efficiently 
and overcome both extracellular and intracellular barri-
ers.11 Liposome and polycationic polymer-based non-viral 
systems are common methods of delivering siRNA in vitro. 
As compared with viral delivery, these methods induce 
less immunogenicity and fewer safety issues.12 Moreover, 
polymer-based non-viral vectors have greater advantages 
than liposomes with respect to safety, convenient large-scale 
production, and physiological stability. The cationic polymer, 
polyethyleneimine (PEI) contains primary, secondary, and 
tertiary amines; therefore, it has the ability to complex with 
both DNA or siRNA, a characteristic known as the “proton 
sponge effect”.13 Various PEI types (branched and linear) 
with varying molecular weights (10, 25, 800 kDa) have 
been successfully used as non-viral gene delivery carriers 
in both in vitro and in vivo studies. However, PEI-based 
gene transfection technology may induce cell cytotoxic-
ity, depending on the molecular weight and concentration 
of the polymer.14 Therefore, in the present study, we have 
developed a PEG-modified PEI polymer, which displays 
reduced cytotoxicity while maintaining considerable gene 
transfection efficiency.15–18 Moreover, PEG modification of 
PEI can increase polymer solubility, protect nanoparticles 
from macrophage uptake, prolong the circulation time of 
nanoparticles in vivo, and decrease non-specific interactions 
with serum protein.19,20
In this study, we synthesized a PEG-modified PEI copo-
lymer and determined its ability to mediate the delivery 
of CD44v6 siRNA. PEG (2 kDa) and PEI (25 kDa) were 
chosen to form the copolymer; their ratio was optimized 
to reduce cytotoxicity and particle size. In addition, siRNA 
and PEG-PEI complexes were formed at different N/P ratios 
(theoretical charge ratio between amino groups of PEG-PEI 
and phosphate groups of siRNA).13,21 For low cytotoxicity 
and high transfection efficiency, PEG-PEI/siRNA, at the most 
suitable N/P ratio, was selected to transfect SGC7901 human 
gastric carcinoma cells.
Materials and methods
Materials and reagents
Poly(ethyleneglycol)-polyethylenimine (PEG; 2 kDa and 
PEI; 25 kDa, respectively) was synthesized by the School 
of Chemistry and Chemical Engineering at Sun Yat-Sen 
University. (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) was obtained from Sigma-
Aldrich (St Louis, MO, USA). The PrimeScript™ RT-PCR 
Kit was purchased from TaKaRa Biotechnology, (Dalian, 
China). Cell culture medium and fetal bovine serum (FBS) 
were purchased from GIBCO (Carlsbad, CA, USA). The 
human gastric carcinoma cell line, SGC-7901, was obtained 
from the Institute of Biochemistry and Cell Biology at the 
Chinese Academy of Sciences (Shanghai, China). siRNA 
targeting human CD44v6, negative control siRNA, and 
FAM-labeled siRNA were purchased from GenePharma 
(Shanghai, China). Antibodies specific for human CD44v6 
were purchased from Bender MedSystems® (Vienna, Aus-
tria). The following siRNA targeting sequences were used: 
siRNA-CD44v6, 5′CAG UGG UUU GGC AAC AGA UTT 3′; 
negative control siRNA, 5′GCG ACG AUC UGC CUA AGA 
3′; and FAM-labeled siRNA, 5′UUC UCC GAA CGU GUC 
ACG UTT 3’.
cell culture
Human gastric carcinoma SGC-7901 cells were cultured 
and maintained in high glucose Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum at 37°C in a fully humidified atmosphere of 
5% CO2.
Preparation of Peg-PeI copolymers
Methoxy N-hydroxysuccinimide polyethylene glycol 
(mPEG2k-NHS) was prepared as described previously.22 To 
synthesize PEG-PEI, 1.25 g of hyperbranched PEI (25 kDa, 
Aldrich) and 1.0 g mPEG-NHS was added to phosphate 
buffered saline (PBS, pH 7.4). The solution was magnetically 
stirred at room temperature overnight. The resulting solution 
was purified by membrane dialysis (molecular weight cutoff: 
7 kDa) in distilled water for 48 hours, and then lyophilized 
to obtain solid PEG-PEI. PEG-PEI was characterized by 
Proton Nuclear magnetic resonance (1H-NMR) in deuterium 
oxide.
Preparation of siRNA-polymer 
nanocomplexes
PEG-PEI copolymers were dissolved to yield different con-
centrations (0.24–1.42 mg/mL), according to various N/P 
ratios. Appropriate volumes of siRNA (20µM) and PEG-
PEI solutions were added to deionized water after which 
it was gently mixed and incubated 10–15 minutes at room 
temperature to induce nanocomplex formation.International Journal of Nanomedicine 2010:5 131
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Zeta potential and size measurements
Nanoparticle size was analyzed using the Zeta-Plus instru-
ment (Brookhaven, NY, USA) at 25°C. Zeta potentials of 
the nanoparticles were measured using the same instrument 
at a 45° angle and 25°C. The data represent the average ± 
standard deviations.
scanning electron microscopic analysis
The morphology of PEG-PEI/siRNA nanocomplexes was 
observed by scanning electron microscopy (SEM; Quanta 
400 FEG). Nanocomplexes were deposited onto a coverslip 
and dried for 2 hours at room temperature. After they were 
gilded, they were observed in the thermal field of the electron 
microscope.
gel retardation assay
Gel electrophoresis was performed to evaluate siRNA 
condensation. PEG-PEI/siRNA complexes were prepared 
at different N/P ratios from 5 to 30, and the complexes were 
loaded onto 1% agarose gels with 6× loading buffer (1 µL) 
and 10× colloidal gold (1 µL). The mixture was separated in 
0.5× Tris/Borate/EDTA (TBE) buffer at 100V for 25 minutes 
siRNA bands were visualized using an ultra violet (UV) 
imaging system (Uvidoc, UVItec Ltd, Cambridge, UK).
MTT assay
SGC7901 cells were grown in 96-well plates at an initial 
density of 9000 cells/well in 200 µL medium and incubated 
for 24 hours prior to the addition of polymers. The cytotox-
icities of PEI and PEG-PEI at different final concentrations 
were tested. Each concentration was analyzed in triplicate. 
In addition, the cytotoxicity of PEG-PEI/siRNA at differ-
ent N/P ratios was also evaluated; Lipofectamine 2000 and 
PEI (1 mg/mL) were used as controls. Transfection was 
performed with 20 pM siRNA per well to form the PEG-PEI/
siRNA complexes. After additional incubation for 48 hours, 
the medium was replaced with 200 µL serum-free medium, 
and 20 µL MTT solution (5 mg/mL) were added per well. 
After 4 hours, 100 µL of DMSO was added. The plate was 
agitated for 10 minutes, and the absorbance of each well was 
recorded with an ELISA reader (Labsystem Dragon, Oy, 
Finland) at 492 nm. The data from three separate experiments 
were calculated as a percentage of viable cells over untreated 
control ± standard deviation.
Transfection efficiency analysis
SGC7901 cells were seeded into 6-well plates at a density 
of 4 × 104 cells per well before transfection. The PEG-
PEI/siRNA complexes were prepared, and according to the 
N/P ratio, from 5 to 30,100 pM FAM-siRNA and copolymer 
solution at different concentrations were added into 500 µL 
PBS. The PEG-PEI/siRNA complexes were gently mixed 
and incubated for 10–15 minutes at room temperature. The 
original cell culture media was replaced with 1 mL of fresh 
and complete DMEM per well. The complexes were added 
to the well drop by drop and then rocked gently for 5 hours 
at 37°C after which the transfection media was exchanged 
with fresh, complete DMEM. The cells were observed under 
the fluorescence microscope (Nikon, Tokyo, Japan), and 
images were recorded.
Sixteen hours after transfection, cells were washed 
with PBS and detached with 0.25% trypsin/EDTA. The 
cells were washed with PBS and resuspended in 500 µL 
PBS. The transfection efficiency was evaluated by scoring 
the percentage of cells with green fluorescence using a 
FACSCalibur system (Becton Dickinson, Franklin Lakes, 
NJ, USA). The data were presented as mean ± standard 
deviation.
RT-PcR analysis
After transfection for 48 hours, RNA was extracted using 
Trizol reagent (Invitrogen, Carlsbad, CA, USA). RT-PCR 
using the PrimeScript RT-PCR Kit was performed follow-
ing the manufacturer’s instructions; 2 µL resulting cDNA 
were subjected to PCR reactions using specific primers. 
Negative control (without cDNA) was used to detect pos-
sible contamination. PCR reaction was as follows: 30 cycles 
including 94°C for 30 seconds, 56°C for 30 seconds, and 
72°C for 30 seconds and 1 cycle at 72°C for 7 minutes. PCR 
products were analyzed on 2% agarose gels. Sequences 
of the CD44v6 primers were as follows: forward, 5′-GGC 
AAC TCC TAG TAG TAC AAC-3’ and reverse, 5′-CAG 
CTG TCC CTG TTG TCG AAT-3′. Sequences of the glyc-
eraldehyde 3-phosphate dehydrogenase (GADPH) primers 
were as follows: forward, 5′-TTC GAC AGT CAG CCG 
GAT CTT C-3′ and reverse, 5′-CTT CTC CAT GGT GGT 
GAA GAC G-3′.
Western blot analysis
After transfection for 72 hours, total protein was extracted 
in RIPA buffer (Beyotime, Shanghai, China) with protease 
inhibitors (PMSF). Protein concentrations were measured 
using the BCA-100 Protein Quantitative Analysis Kit 
(Shenergy Biocolor, Shanghai, China). Equal amounts of 
total proteins were separated in 10% sodium dodecyl sulfate 
(SDS) polyacrylamide gel and transferred to polyvinylidene International Journal of Nanomedicine 2010:5 132
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difluoride (PVDF) membranes. The membranes were blocked 
in 5% nonfat dry milk in Tris-buffered saline tween-20 
(TBST) for 2 hours at room temperature and incubated with 
mouse anti-CD44v6 antibodies (1:1000, Bender, Austria) 
overnight at 4°C. After three washes with TBST, membranes 
were incubated with anti-mouse IgG-horseradish-peroxidase 
(1:5000, Jackson, MI, USA) for 1 hour at room temperature. 
Enhanced chemiluminescence detection reagent was used, 
and the protein bands were visualized after exposition with 
x-ray film. GADPH expression was used as the housekeeping 
gene control. Images analyses were performed with Quantity 
One Software.
statistical analysis
Data were expressed as mean ± standard error (SE). 
All statistical analyses were performed with SPSS 
11.0 software. analysis of variance (ANOVA) analysis 
was used, and a P-value 0.05 was considered statisti-
cally significant.
Results
syntheses of Peg-PeI copolymers
PEG-PEI was synthesized through the conjugation of PEG-
NHS to PEI. 1H NMR analysis of the dialyzed PEI-PEG 
revealed prominent chemical shift of protons from PEG 
(—OCH2CH2—, 3.65 ppm; CH3O—, 3.38 ppm) and PEI 
(—CH2CH2NH—, 2.5–2.9 ppm), indicating that PEG chains 
were successfully grafted onto PEI chains. PEG graft-
ing density of PEI was 9.9 as characterized by 1H NMR 
(Figure 1).
size and zeta potential of Peg-PeI/siRNA 
complexes
The size and zeta potential of PEG-PEI/siRNA complexes 
varied at different N/P ratios; N/P ratios from 5 to 30 are 
shown in Table 1. At N/P 5, the size of the nanoparticle was 
approximately 174.6 ± 1.2 nm. The size reached to 267.7 ± 
1.8 nm at N/P 10, then decreased gradually to 192.1 ± 2.8 nm 
at N/P 30. The size distribution of PEG-PEI/siRNA at N/P 
15 is shown in Figure 2; the size distribution of the complexes 
was between 180 and 242 nm whereas the remaining particles 
over 800 nm might be not complex well. The zeta potential 
was negative at N/P 5 and positive at N/P 10, increasing 
linearly as the ratio of PEG-PEI increased.
scanning electron microscope
PEG-PEI/siRNA nanoparticles were well-complexed at 
N/P 15; therefore these particles were observed under SEM. 
The nanoparticles appeared spherical, uniform in size, and 
well-dispersed. The size of the nanoparticles at N/P 15 was 
approximately 240 nm, which was similar to that measured 
with the Zeta-Plus instrument (Figure 3).
gel retardation assay
The positive charges of PEG-PEI can neutralize the negative 
charges of the phosphate groups within the siRNA backbone, 
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Figure 1 1h-NMR spectra of mPeg-cOOh (A) and mPeg-PeI (B).
Abbreviation: Peg-PeI, polyethylene glycol-polyethyleneimine.
Table 1 The particle size and zeta potential of Peg-PeI/siRNA 
complexes
N/P ratio 5 10 15 30
size (nm) 174.6 ± 1.2 267.7 ± 1.8 241.5 ± 3.8 192.1 ± 2.8
Zeta  
potential (mV)
-5.76 ± 1.1 3.01 ± 0.1 16.0 ± 1.5 26.9 ± 0.8
Abbreviation: Peg-PeI, polyethylene glycol-polyethyleneimine.
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Figure 2 size distribution of Peg-PeI nanoparticles at N/P 15 measured by Zeta 
Plus instrument.
Notes: The size distribution of two parts in the graph was respectively 180–242 nm, 
845–1130 nm.
Abbreviation: Peg-PeI, polyethylene glycol-polyethyleneimine.International Journal of Nanomedicine 2010:5 133
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thus retarding the siRNA mobility (Figure 4). Naked siRNA 
was used as the control group. siRNA bands decreased with 
increasing N/P ratios (from 2.5 to 30). When the N/P was 10, 
the band remained bright and completely disappeared when 
the N/P was 30, indicating that the negatively charged siRNA 
could be neutralized entirely at this N/P value.
cell viability analysis
SGC7901 cells were incubated at different concentrations of 
PEG-PEI and PEI for 48 hours, and the cell viability was mea-
sured using the MTT assay (Figure 5A). Cells incubated with 
pure media, without treatment, were considered as controls, 
and the cell viability values was set at 100%. Cytotoxicity 
of PEG-PEI was lower than that observed with PEI at the 
same concentrations (P  0.05). When the concentrations 
were over 10 µg/mL, increased toxicity was detected with 
PEG-PEI and PEI. As shown in Figure 5B, the cell viability 
in the presence of PEG-PEI/siRNA complexes at different 
N/P ratios was tested after transfection for 48 hours. PEI 
25 kDa/siRNA and Lipofectamine 2000/siRNA complexes 
were used as controls. The cytotoxicity of PEG-PEI/siRNA 
complexes increased with higher N/P ratios. When the N/P 
Figure 3 scanning electron microscopy (seM) images of Peg-PeI/siRNA nanoparticles at N/P 15 (120000× and 7500× respectively).
Abbreviations: Peg-PeI, polyethylene glycol-polyethyleneimine; N/P, charge ratio between amino groups of Peg-PeI and phosphate groups of siRNA.
Figure 4 gel electrophoresis of Peg-PeI/siRNA complexes at different N/P ratios.
Notes: Lane1: naked siRNA; Lane 2: Peg-PeI/siRNA at N/P 2.5; Lane 3: Peg-PeI/
siRNA at N/P 5; Lane 4: Peg-PeI/siRNA at N/P 10; Lane 5: Peg-PeI/siRNA at N/P 
15; Lane 6: Peg-PeI/siRNA at N/P 30.
Abbreviations: Peg-PeI, polyethylene glycol-polyethyleneimine; N/P, charge ratio 
between amino groups of Peg-PeI and phosphate groups of siRNA.
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ratio using PEG-PEI/siRNA reached 15, the cell viability 
was 80.4% ± 5.6%, which was similar to that observed with 
Lipofectamine 2000/siRNA. When the N/P ratio was 30, the 
cell viability of cells transfected with PEG-PEI/siRNA was 
73.8% ± 4.8%, which was higher than that of PEI/siRNA.
In vitro transfection assay
FAM-(carboxyfluorescein)-labeled siRNA was used in 
formation of the complexes, and transfection efficiency of 
PEG-PEI/siRNA complexes was evaluated with a fluores-
cence microscope and flow cytometry in SGC7901 cells. 
Lipofectamine 2000 and PEI (25 kDa) were used as positive 
controls. The transfection efficiencies appeared different at 
various N/P ratios (Figures 6A and 6B); higher N/P ratios 
resulted in increased transfection efficiencies. For example, 
at N/P 5, the fluorescence intensity was weakest, increasing 
from N/P 5 to 30. Lipofectamine 2000 and PEI (25 kDa) also 
displayed high transfection efficiencies. The transfection 
efficiency of each group was evaluated in three independent 
experiments using flow cytometry. As shown in Figure 6B, 
the transfection efficiencies of PEG-PEI/siRNA at N/P 15 
and 30 were 75.5% ± 2.4% and 75.6% ± 9.2%, respectively. 
Although there was a minor increase, the transfection effi-
ciencies of PEG-PEI/siRNA at N/P 30 were higher than that 
of Lipofectamine 2000/siRNA and PEI/siRNA.
The gene silencing effect  
of cD44v6 siRNA
PEG-PEI/siRNA at N/P 15 was chosen for transfection of 
the SGC7901 cells. The ability of siRNA to reduce CD44v6 
mRNA and protein expression was analyzed using RT-PCR 
and Western blot analysis, respectively. Expression of 
CD44v6 was down-regulated by siRNA targeted to CD44v6 
(Figure 7), indicating that siRNA-CD44v6 could suppress 
the expression of CD44v6 expression at the mRNA level 
while the negative control siRNA had no obvious effect on 
CD44v6 expression. The gene silencing effect of siRNA was 
further confirmed by Western blot analysis (Figure 8). The 
expression of CD44v6 protein was decreased using siRNA-
CD44v6 to 59.7% ± 3%.
Discussion
RNAi-mediated silencing of important oncogenic regulators 
plays a major role in cancer therapy. For efficient cancer 
N/P = 5 N/P = 10 N/P = 15 N/P = 30 PEI Lipo2000
Figure 6a Fluorescence microscope images of sgc-7901 cells transfected with Peg-PeI/siRNA complexes at N/P = 5, 10, 15, 30, PeI (25 KD) and Lipo2000, respectively.
Abbreviations: Peg-PeI, polyethylene glycol-polyethyleneimine; N/P, charge ratio between amino groups of Peg-PeI and phosphate groups of siRNA.
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therapy, siRNA should be stable and efficiently delivered 
into the target tissue and easily taken up by the cancer cells.23 
In this study, PEG (2 kDa)-PEI (25 kDa) was synthesized to 
form nanometer-sized complexes with siRNA. Reports have 
shown that adequate size and positive potential are essential 
for enhanced delivery of nanoparticles into cells. The size and 
potential of the complexes below N/P 10 were not suitable for 
cell transfection (Table 1) because PEG-PEI and siRNA could 
not form a complex of adequate size and positive potential.
Agarose electrophoresis was used to evaluate siRNA-
copolymer affinity. When PEG-PEI/siRNA complexes 
formed, the negatively charged siRNA could be neutralized 
by the positively charged polycations. Thus, insertion of 
colloidal gold into the siRNA was impeded. With N/P ratios 
increasing, siRNA was complexed more effectively with 
the polycations; the insertion of colloidal gold into siRNA 
double-strands was blocked to a higher extent and conse-
quently the brightness of the siRNA bands weakened.24 In this 
study, at N/P 10, the complete neutralization of the siRNA 
was observed. At N/P 30, siRNA was entirely wrapped by 
PEG-PEI, producing a fluorescence quenching phenomenon. 
Therefore, it could be considered that siRNA was completely 
complexed with PEG-PEI at N/P ratios 10. Interaction of 
DNA or siRNA with cationic polymers could protect the 
condensed DNA or siRNA from enzymatic degradation,25,26 
making it more effective for cellular transfection.
Increased transfection efficiency of PEG-PEI/siRNA was 
observed at higher N/P ratios, reaching the highest transfec-
tion efficiency at N/P 15. No major increase appeared at N/P 
30 possibly because over-condensation at high N/P values is 
not favorable for intracellular release of nucleic acids.27,28
Cytotoxicity of the PEG-PEI/siRNA was also analyzed 
using the MTT assay. Cytotoxicity induced by PEG-PEI was 
obviously lower than PEI, which suggests that PEG reduced 
the toxicity of the heavily cationic PEI portion of copolymer 
structure.13 When the concentration of PEG-PEI in the culture 
medium was less than 10 µg/mL, the biosafety of this delivery 
agent was improved. As a non-viral delivery system, Lipo-
fectamine 2000 is widely used in studies analyzing RNAi. 
However, some reports have indicated that Lipofectamine 
2000 has a high toxicity.29,30 In this study, when N/P values 
were below 15, the cell toxicity of PEG-PEI/siRNA was 
lower than that of Lipofectamine 2000/siRNA, indicating that 
PEG-PEI may be a promising non-viral gene delivery carrier 
with higher transfection efficiency and lower cytotoxicity.
Considering the high transfection efficiency and low 
cytotoxicity, PEG-PEI/siRNA at N/P 15 this was chosen to 
transfect SGC7901 cells. RT-PCR and Western blot analyses 
indicated effective gene silencing of CD44v6 expression in 
SGC7901 cells when PEG-PEI served as a carrier. The results 
showed that PEG modified-PEI (25 kDa) delivered siRNA 
into SGC7901 cells and released them effectively.
Compared with PEI (25 kDa) and Lipofectamine 2000, 
PEG-PEI has more advantages, such as increased transfection 
efficiency and improved cell viability. However, this carrier 
may be further improved. We are dedicated to research on the 
linkage of single-chain antibody and PEG-PEI (25 kDa). The 
study will improve the transfection efficiency and minimize 
the damage of siRNA to normal gastric cells.
Conclusion
In this study, we developed a nano-sized polymeric system 
for delivering siRNA to inhibit the expression of CD44v6 in 
gastric cancer cells in vitro. Compared with Lipofectamine 
2000 or PEI (25 kDa), the copolymer had advantages such 
as low cytotoxicity, high transfection efficiency, low cost, 
with easy adjustment of its structure. Thus, PEG-PEI might 
be a promising gene carrier for siRNA in gene therapy of 
gastric cancer. Moreover, this study provided a foundation 
M 1 2 3 4 M 1 2 3 4
1. GADPH 2. CD44v6
Figure 7 The result of RT-PcR analysis after transfection with Peg-PeI/siRNA.
Notes: M: marker. From the bottom: 100 bp, 200 bp, 300 bp, 400 bp, 500 bp, 700 bp, 
1000 bp. Lane 1: siRNA-cD44v6/Peg-PeI complexes group. Lane 2: negative control 
siRNA/Peg-PeI complexes group. Lane 3: no treatment group. Lane 4: negative control 
group without RNA template. gADPh was used as a control.
Abbreviations: Peg-PeI, polyethylene glycol-polyethyleneimine; N/P, charge ratio 
between amino groups of Peg-PeI and phosphate groups of siRNA; gADPh, glycer-
aldehyde 3-phosphate dehydrogenase. 
2 1 3
CD44v6(80 KD)
GADPH(37 KD)
Figure 8 The result of Western blot analysis after transfection with Peg-PeI/
siRNA.
Notes: Lane 1: siRNA-cD44v6/Peg-PeI complexes group. Lane 2: negative control 
siRNA/Peg-PeI complexes group. Lane 3: no treatment group.
Abbreviations: Peg-PeI, polyethylene glycol-polyethyleneimine; gADPh, glyceral-
dehyde 3-phosphate dehydrogenase.International Journal of Nanomedicine 2010:5
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